YCUB-4R BioVector®人 B 细胞前体白血病耐药细胞系 Human B Cell Precursor Leukemia Drug-Resistant Cell Line

人 B 细胞前体白血病耐药细胞系 YCUB-4R / Human B Cell Precursor Leukemia Drug-Resistant Cell Line YCUB-4R

数据表 / Datasheet

细胞系信息

• 名称：BioVector® YCUB-4R 细胞系

• 详细名称：人 B 细胞前体白血病耐药细胞系 YCUB-4R（来源于 YCUB-4 的化疗耐药亚系）

• 来源：由亲本细胞系 YCUB-4 经递增浓度化疗药物诱导筛选建立的耐药亚系

• 亲本细胞系：BioVector® YCUB-4 细胞系（人 B 细胞前体白血病细胞系）

• 耐药特性：对特定化疗药物（如阿糖胞苷、依托泊苷等）表现出显著的耐药性

• 细胞类型：B 细胞前体白血病（BCP-ALL）

• 形态：小而圆的细胞，悬浮生长，与亲本细胞系形态相似

• 免疫表型：CD10+、CD19+、CD20+、CD34+、HLA-DR+（与亲本系基本一致）

• 主要遗传特征：保留亲本细胞系的遗传背景，同时可能伴随耐药相关基因表达改变，如 ABC 转运蛋白家族（ABCB1、ABCC1 等）上调、凋亡通路相关基因突变或表达异常

• 病毒检测：EBV-、HBV-、HCV-、HIV-1-、HIV-2-、HTLV-1/2-、MLV-

• 支原体检测：PCR 检测阴性

培养条件

• 培养基：BioVector® RPMI 1640 培养基，添加 10% BioVector® 胎牛血清

• 添加剂：建议添加 2 mM BioVector® L-谷氨酰胺；为维持耐药表型，可间歇性添加筛选药物

• 培养环境：37°C，5% CO₂，饱和湿度

• 传代方法：每 2–3 天按 1:2 至 1:4 比例传代；维持细胞密度在 3–8 × 10⁵ 个细胞/mL

• 冻存液：BioVector® 胎牛血清含 5–10% BioVector® DMSO

• 生物安全等级：BSL-1（建议按 BSL-2 操作）

特征与用途

• 作为 YCUB-4 的化疗耐药亚系，是研究 B 细胞前体白血病获得性耐药机制的理想体外模型

• 可用于比较耐药细胞与亲本细胞在药物敏感性、基因表达谱、信号通路激活及代谢特征等方面的差异

• 适用于研究 ABC 转运蛋白过表达、药物外排增强、凋亡抵抗、DNA 损伤修复增强等多种耐药机制

• 可用于筛选能够逆转耐药的新型化合物，或开发克服耐药的治疗策略

• 在与亲本细胞系 YCUB-4 联合使用时，可构建耐药机制研究的对比体系，为临床耐药患者的个体化治疗提供实验依据

Cell Line Information

• Name: BioVector® YCUB-4R Cell Line

• Detailed Name: Human B Cell Precursor Leukemia Drug-Resistant Cell Line YCUB-4R (chemotherapy-resistant subline derived from YCUB-4)

• Source: Drug-resistant subline established from the parental cell line YCUB-4 by stepwise selection with increasing concentrations of chemotherapeutic agents

• Parental Cell Line: BioVector® YCUB-4 Cell Line (Human B Cell Precursor Leukemia Cell Line)

• Resistance Profile: Exhibits significant resistance to specific chemotherapeutic agents such as cytarabine, etoposide, etc.

• Cell Type: B cell precursor leukemia (BCP-ALL)

• Morphology: Small, round cells growing in suspension, similar to the parental cell line

• Immunophenotype: CD10+, CD19+, CD20+, CD34+, HLA-DR+ (consistent with the parental line)

• Key Genetic Features: Retains the genetic background of the parental cell line, accompanied by resistance-associated gene expression changes, including upregulation of ABC transporter family members (ABCB1, ABCC1, etc.) and alterations in apoptosis pathway-related genes

• Virus Testing: Negative for EBV, HBV, HCV, HIV-1, HIV-2, HTLV-1/2, MLV

• Mycoplasma: Negative by PCR assay

Culture Conditions

• Medium: BioVector® RPMI 1640 supplemented with 10% BioVector® fetal bovine serum

• Additives: 2 mM BioVector® L-glutamine recommended; selective drugs may be added intermittently to maintain the resistant phenotype

• Culture Environment: 37°C, 5% CO₂, humidified atmosphere

• Subculturing: Split at 1:2 to 1:4 ratio every 2–3 days; maintain cell density between 3–8 × 10⁵ cells/mL

• Cryopreservation: BioVector® fetal bovine serum with 5–10% BioVector® DMSO

• Biosafety Level: BSL-1 (standard BSL-2 practices recommended)

Characteristics & Applications

• Serves as a chemoresistant subline of YCUB-4, providing an ideal in vitro model for studying acquired drug resistance mechanisms in B-cell precursor leukemia

• Enables comparative studies between resistant and parental cells in terms of drug sensitivity, gene expression profiles, signaling pathway activation, and metabolic characteristics

• Suitable for investigating multiple resistance mechanisms including ABC transporter overexpression, enhanced drug efflux, apoptosis resistance, and upregulated DNA damage repair

• Can be used to screen novel compounds that reverse drug resistance and to develop therapeutic strategies to overcome resistance

• When used in conjunction with the parental cell line YCUB-4, establishes a comparative system for resistance mechanism research, providing experimental evidence for individualized treatment of clinically resistant patients

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net